About C2 Therapeutics
C2 Therapeutics is a company based in Redwood City (United States) founded in 2007 was acquired by Pentax Medical in January 2017. C2 Therapeutics has raised $28.96 million across 9 funding rounds from investors including Pentax Medical and Main Line Equity Partners. The company has 16 employees. C2 Therapeutics operates in a competitive market with competitors including EndoChoice, EndoGastric Solutions, CoapTech, SafeStitch and Endo Tools Therapeutics, among others.
- Headquarter Redwood City, United States
- Employees 16
- SectorsHealthcare
- Website c2therapeutics.com
- Social LinkedIn
- Acquired by Pentax Medical (Jan 2017)
- Total Equity Funding$28.96M (USD)
in 9 rounds
- Latest Funding Round$6.3M (USD), Series B
Dec 2016
- InvestorsPentax Medical
& 1 more
- Employee Count16
- Acquired byPentax Medical
(Jan 2017)
Funding Insights of C2 Therapeutics
C2 Therapeutics has successfully raised a total of $28.96M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $6.3 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.96M
- Total Rounds 9
- Last Round Series B — $6.3M
- First Round $320,000
(May 2007)
- Investors Count 1
All 9 funding rounds of C2 Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $6.3M | Series B | – | – | – |
| Oct 2014 | $11.63M | Series B | – | – | – |
| Sep 2014 | $2.55M | Series B | – | – | – |
| Jun 2014 | – | Series B | – | – | |
| May 2013 | $2.55M | Series A | – | – | – |
| Apr 2012 | $2.39M | Series A | – | – | – |
| Jun 2009 | $3.02M | Series A | – | – | – |
| Jun 2008 | $210,000 | Seed | – | – | – |
| May 2007 | $320,000 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in C2 Therapeutics
C2 Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Pentax Medical and Main Line Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Main Line Equity Partners is engaged in private equity investments. | – | mainlineequity.com | Ardmore, USA | |
Endoscopic imaging devices and solutions are developed and marketed. | 1976 | pentaxmedical.com | Montvale, United States |
Investor details for C2 Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of C2 Therapeutics
4 dated milestones of C2 Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded C2 Therapeutics is founded.
- Funding First funding round of $320K.
- Funding Latest funding round, Series B, of $6.3M.
- Exit Acquired by Pentax Medical.
Competitors of C2 Therapeutics
C2 Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EndoChoice, EndoGastric Solutions, CoapTech, SafeStitch and Endo Tools Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| endochoice.com | 2008 | Alpharetta, United States | $115.96M | 414 | Devices, systems, and services are provided for GI specialists. | |
| endogastricsolutions.com | 2002 | San Mateo, United States | $355.2M | 80 | Incisionless transoral procedures for upper GI diseases are developed. | |
| coaptech.com | 2016 | Baltimore, United States | $16.52M | – | Minimally invasive gastrostomy feeding tube placement method is developed. | |
| safestitch.com | 2005 | Miami, United States | $7.58M | 167 | Medical devices for gastrointestinal and bariatric surgery are developed. | |
| endotools.be | 2008 | Charleroi, Belgium | $18.67M | 12 | Endoscopic catheters for precision in gastroenterology are developed. | |
| endostim.com | 2009 | St. Louis, United States | $75.78M | – | Implant to treat GERD | |
| dpbioinnovations.com | 2015 | San Diego, United States | – | – | Repairing system for damaged esophagus | |
| reliefband.com | 2015 | Chicago, United States | $6M | 10 | Wearable device is developed for nausea and vomiting relief. |
Detailed competitors of C2 Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to C2 Therapeutics
10 companies that operate in the same segment as C2 Therapeutics (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about C2 Therapeutics
C2 Therapeutics was founded in 2007.
C2 Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
C2 Therapeutics is a funded company, having raised a total of $28.96M across 9 funding rounds to date. The company's 1st funding round was a Seed of $320K, raised on May 2007.
C2 Therapeutics has 16 employees.
C2 Therapeutics develops ablation therapies to treat diseases of the gastrointestinal tract. The company has developed a cryoballoon focal ablation system for endoplasmic ablation of barretts tissue. As of October 2015, company has received CE mark and coldplay cryoballoon ablation system is available for sale in western Europe. Company has also received USFDA 510k approval for both coldplay cryoballoon full ablation system and coldplay cryoballoon swipe ablation system.
C2 Therapeutics's top competitors include CoapTech, Endo Tools Therapeutics and EndoChoice.
C2 Therapeutics has 2 investors. Key investors include Pentax Medical, and Main Line Equity Partners.
Yes. C2 Therapeutics was acquired by Pentax Medical in January 2017.